506153308 07/14/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6200040

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
BIOELECTRON TECHNOLOGY CORPORATION	10/25/2019

RECEIVING PARTY DATA

Name:	PTC THERAPEUTICS, INC.
Street Address:	100 CORPORATE COURT
City:	SOUTH PLAINFIELD
State/Country:	NEW JERSEY
Postal Code:	07080-2449

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11445582

CORRESPONDENCE DATA

Fax Number: (415)393-9887

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (415) 954-0200

Email: tanisha.lawrence-caceres@squirepb.com
Correspondent Name: SQUIRE PATTON BOGGS (US) LLP
Address Line 1: 275 BATTERY STREET, SUITE 2600

Address Line 2: ATTN: JANICE V. RICE

Address Line 4: SAN FRANCISCO, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	112738.00006
NAME OF SUBMITTER:	JANICE V. RICE
SIGNATURE:	/Janice V. Rice/
DATE SIGNED:	07/14/2020

Total Attachments: 41

source=Patent Assignment#page1.tif source=Patent Assignment#page2.tif source=Patent Assignment#page3.tif source=Patent Assignment#page4.tif source=Patent Assignment#page5.tif

> PATENT REEL: 053210 FRAME: 0036

506153308

_	
s	ource=Patent Assignment#page6.tif
s	ource=Patent Assignment#page7.tif
s	ource=Patent Assignment#page8.tif
s	ource=Patent Assignment#page9.tif
s	ource=Patent Assignment#page10.tif
s	ource=Patent Assignment#page11.tif
s	ource=Patent Assignment#page12.tif
s	ource=Patent Assignment#page13.tif
s	ource=Patent Assignment#page14.tif
s	ource=Patent Assignment#page15.tif
s	ource=Patent Assignment#page16.tif
s	ource=Patent Assignment#page17.tif
s	ource=Patent Assignment#page18.tif
s	ource=Patent Assignment#page19.tif
s	ource=Patent Assignment#page20.tif
	ource=Patent Assignment#page21.tif
s	ource=Patent Assignment#page22.tif
	ource=Patent Assignment#page23.tif
s	ource=Patent Assignment#page24.tif
s	ource=Patent Assignment#page25.tif
s	ource=Patent Assignment#page26.tif
s	ource=Patent Assignment#page27.tif
	ource=Patent Assignment#page28.tif
	ource=Patent Assignment#page29.tif
	ource=Patent Assignment#page30.tif
	ource=Patent Assignment#page31.tif
	ource=Patent Assignment#page32.tif
	ource=Patent Assignment#page33.tif
	ource=Patent Assignment#page34.tif
	ource=Patent Assignment#page35.tif
	ource=Patent Assignment#page36.tif
	ource=Patent Assignment#page37.tif
	ource=Patent Assignment#page38.tif
	ource=Patent Assignment#page39.tif
	ource=Patent Assignment#page40.tif
s	ource=Patent Assignment#page41.tif

PATENT ASSIGNMENT

THIS ASSIGNMENT OF PATENTS (this "<u>Assignment</u>"), including all schedules attached hereto, is made effective October 25, 2019, between BioElectron Technology Corporation, a Delaware corporation ("<u>Assignor</u>") and PTC Therapeutics, Inc., a Delaware corporation ("<u>Assignee</u>"). Assignor and Assignee may be referred to in this Assignment each as a "Party" and collectively as the "Parties."

WHEREAS, Assignor and Assignee are parties to an Asset Purchase Agreement, dated October 1, 2019 (the "Agreement"); and

WHEREAS, pursuant to the Agreement, the Parties have agreed that Assignor would transfer, or cause to be transferred, to Assignee certain patents, patent applications, utility models, design registrations and certificates of invention and other governmental grants for the protection of inventions or industrial designs (including all related continuations, continuations-in-part, divisionals, reissues and reexaminations), to the extent used or intended to be used by any member of the Seller Group in the conduct of, or otherwise related to, any of the Products or the Business, including, but not limited to, those identified on Schedule A hereto (all of the foregoing being referred to herein as the "Assigned Patents").

NOW, THEREFORE, in consideration of the execution of the Agreement, the payment of the consideration stipulated in the Agreement, the mutual promises and covenants hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound thereby, the Parties agree as follows:

- 1. All capitalized terms not otherwise defined herein, as used in this Assignment, shall have the respective meanings ascribed to such terms in the Agreement.
- Assignor hereby assigns to Assignee all right, title and interest in, to and under the Assigned Patents, including (i) all rights in applications anywhere in the world claiming priority thereto, (ii) all rights to claim priority thereto, (iii) all reissues, continuations, continuations-in-part, divisionals, reexaminations and foreign equivalents thereof, (iv) all letters patent that may be granted on any of the patent applications included therein, (v) all income and payments now or hereafter due or payable with respect thereto, (vi) all causes of action in law or equity relating thereto, and (vii) all rights to sue, counterclaim and recover for past, present and future infringement of the rights assigned, the same to be held and enjoyed by Assignee, its successors and assigns at least as fully and entirely as the same would have been held and enjoyed by Assignor had no sale and assignment of said Assigned Patents been made.
- 3. Assignor further agrees to execute such further documents reasonably required by Assignee to secure and enforce the rights granted to Assignee under this Assignment.
- 4. Assignee may record this Assignment with the United States Patent and Trademark Office ("<u>USPTO</u>") and with comparable offices in other jurisdictions throughout the world. All costs associated with any such registrations or recordations shall be paid by Assignee. Assignor hereby authorizes and requests the Commissioner for Patents of the USPTO, and any Official of any country or countries foreign to the United States whose duty is to record documents evidencing

ActiveUS 176470133v.2

ownership of patents and patent applications to record Assignee as owner of the Patents, including any reissues, continuations, continuations-in-part, divisionals, or reexaminations thereof and foreign equivalents thereto.

- 5. Assignor hereby authorizes and requests the Commissioner for Patents of the USPTO, and any Official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue all letters patent related to the Assigned Patents to the Assignee, its successors, legal representatives, and assigns, in accordance with the terms of this Assignment.
- 6. This Assignment shall inure to the benefit of and be binding upon the Parties and their respective successors and permitted assigns.
- 7. This Assignment shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware.
- 8. This Assignment may be executed in counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each Party hereto and delivered to the other Party, it being understood that each Party need not sign the same counterpart. This Assignment may be executed and delivered by facsimile or by an electronic scan delivered by electronic mail.
- 9. Each of the Assignor and Assignee by its execution of this Assignment hereby acknowledges and agrees that neither the representations and warranties, nor the rights and remedies of the parties under the Agreement shall be deemed to be enlarged, diminished, modified or altered in any way by this Assignment. In the event of any conflict between the Agreement and this Assignment, the terms of the Agreement shall control.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed by their duly authorized officers as of the date first written above.

BIOELECTRON TECHNOLOGY CORPORATION

Name: Matthew Klein

Title: Chief Executive Officer

ACCEPTED:

PTC THERAPEUTICS, INC.

By: Name: Stuart W. Peltz

Title: Chief Executive Officer

[Signature Page to Patent Assignment]

IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed by their duly authorized officers as of the date first written above.

BIOELECTRON TECHNOLOGY CORPORATION

By: _______Name: Matthew Klein

Title: Chief Executive Officer

ACCEPTED:

PTC THERAPEUTICS, INC.

Name: Stuart W. Peltz

Title: Chief Executive Officer

[Signature Page to Patent Assignment]

REEL: 053210 FRAME: 0041

Schedule A

(see attached)

[Schedule A to Patent Assignment -- Page 1]

ActiveUS 176470133v.2

BioElectron Patent Docket ² (as of 10/23/2019)

MITOCHONDRIAL DISEASES AND OTHER CONDITIONS					
222					
	2610152 4/10	11/28/2007	2610152	S	ED0001CA
AND MODULATIONS OF ENERGY BIOMARKERS					
MITOCHONDRIAL DISEASES AND OTHER CONDITIONS		نىدىن <u>ئ</u> ۆرۈر			
12/17/2014 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF	1888059 12/1	11/21/2007	6784530.5	BG	ED0001BG
AND MODULATIONS OF ENERGY BIOMARKERS					
MITOCHONDRIAL DISEASES AND OTHER CONDITIONS					DIV3
12/26/2018 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF	2564843 12/2	11/30/2012	12195108.1	BE	ED0001BE-
AND MODULATIONS OF ENERGY BIOMARKERS		4			
MITOCHONDRIAL DISEASES AND OTHER CONDITIONS				••••••	
1/11/2017 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF	2471530 1/1:	3/30/2012	12162555.2	ЭВ	ED0001BE-DIV
AND MODULATIONS OF ENERGY BIOMARKERS					
MITOCHONDRIAL DISEASES AND OTHER CONDITIONS		, de la comp			
12/17/2014 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF	1888059 12/:	11/21/2007	6784530.5	ΒE	ED0001BE
AND MODULATIONS OF ENERGY BIOMARKERS			***************************************		
MITOCHONDRIAL DISEASES AND OTHER CONDITIONS		<i>د</i> دد زده د			DIV3
12/26/2018 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF	2564843 12/	11/30/2012	12195108.1	ΑŢ	ED0001AT-
AND MODULATIONS OF ENERGY BIOMARKERS		10000000000000000000000000000000000000			
MITOCHONDRIAL DISEASES AND OTHER CONDITIONS	er e 2000	<u>.</u>			
1/11/2017 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF	2471530 1/1	3/30/2012	12162555.2	ΑŢ	ED0001AT-DIV
AND MODULATIONS OF ENERGY BIOMARKERS		-			
MITOCHONDRIAL DISEASES AND OTHER CONDITIONS					
12/17/2014 REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF	12/	11/21/2007	6784530.5	ΑŢ	ED0001AT
Issue Date Title		Filing Date	Number	Code	כוופוור אפו
	Patent]]	Application	Country	

² EP and EA cases that have entered validation stage are shown in *italics*.

Emission of the second	•	*			· · · · · · · · · · · · · · · · · · ·	the control of the co
Client Ref	Code	Number	Filing Date	Number	Issue Date	Title
ED0001CA-DIV	S	2996149	2/23/2018			REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CH	유	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
and the second						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CH-DIV	£	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CH-	9	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3	<u> روند</u>			, g		MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
		······································				AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CY		6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
*****				v 10.10		MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
FD0001CZ	CZ	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CZ-DIV	2	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
	مبيميم		an turi		d222330	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DE	DΕ	6784530.5	11/21/2007	602006044033.2	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
				211100	*****	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DE-DIV	DE	12162555.2	3/30/2012	602006051548.0	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
dennimentalismente de la constante de la const		The state of the s				AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DE-	PE.	12195108.1	11/30/2012	602006057172.0	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3	•••••		••••			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
					The second secon	

Client Ref	Code	Number	Filing Date	Number	Issue Date	Title
ED0001DK	밎	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
	33				i i	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DK-DIV	P	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
		N				MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DK-	묫	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EA	EΑ	200702622	12/25/2007	016226	03/30/2012	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
		58	••••••			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EA-DIV	ΕA	201101668	12/22/2011		*****	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EE	E	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
					i egilista	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EP	ΕÞ	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EP-DIV	ΕP	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
95						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED-0001EP-	ΕP	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3	:: -4					MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001ES	ES	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
			۸.			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
		***************************************	-	***************************************		AND MODULATIONS OF ENERGY BIOMARKERS

Cilient Ref		7	A			A. Marie Commission of the Com	
DOIES-DIV ES 12162555.2 3/30/2012 2471530 1/11/2017 DOIES- ES 12195108.1 11/30/2012 2564843 12/26/2018 DOIFH FI 6784530.5 11/21/2007 1888059 12/17/2014 DOIFH-DIV FI 12162555.2 3/30/2012 2471530 1/11/2017 DOIFH-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 DOIFR-DIV FR 6784530.5 11/21/2007 1888059 12/17/2014 DOIFR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 DOIFR-DIV FR 12162555.2 3/30/2012 2564843 12/26/2018 DOIFR-DIV GB 6784530.5 11/30/20012 2564843 12/26/2018 DOIGB-DIV GB 6784530.5 11/21/2007 1888059 12/11/2017 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	Client Ref	Code	Number	Filing Date	Number	Issue Date	Title
DO1ES- ES 12195108.1 11/30/2012 2564843 12/26/2018 DO1FI FI 6784530.5 11/21/2007 1888059 12/17/2014 D01FI-DIV FI 12162555.2 3/30/2012 2471530 1/11/2017 D01FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 D01FR-DIV FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 12/17/2014	ED0001ES-DIV	ES	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DOIES- ES 12195108.1 11/30/2012 2354843 12/26/2018 DOIFI-DIV FI 6784530.5 11/21/2007 1888059 12/17/2014 DO1FI-DIV3 FI 12162555.2 3/30/2012 2471530 1/11/2017 D01FR-DIV FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR-BOIV FR 12195108.1 11/30/2012 2471530 1/11/2017 D01FR-BOIV FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB-BOIV GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-BOIV GB 12162555.2 3/30/2012 2471530 1/11/2017						editore	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
201ES- ES 12195108.1 11/30/2012 2564843 12/26/2018 201FI-DIV FI 12182555.2 3/30/2012 2471530 12/17/2014 201FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 201FR-DIV FR 6784530.5 11/21/2007 1888059 12/17/2014 201FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 201FR-DIV FR 12195108.1 11/30/2012 2471530 1/11/2017 201FR-DIV GB 6784530.5 11/21/2007 1888059 12/17/2014 201GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017							AND MODULATIONS OF ENERGY BIOMARKERS
DO1FI FI 6784530.5 11/21/2007 1888059 12/17/2014 D01FI-DIV FI 12162555.2 3/30/2012 2471530 1/11/2017 D01FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 D01FR-DIV FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR-DIV FR 12195108.1 11/30/2012 2564843 12/26/2018 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB-DIV GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2564843 12/17/2014	ED0001ES-	ES	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
D01FI FI 6784530.5 11/21/2007 1888059 12/17/2014 D01FI-DIV FI 12162555.2 3/30/2012 2471530 1/11/2017 D01FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 D01FR FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2564843 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	DIV3						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
DOIFI FI 6784530.5 11/21/2007 1888059 12/17/2014 DOIFI-DIV FI 12162555.2 3/30/2012 2471530 1/11/2017 DOIFI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 DOIFR-DIV FR 6784530.5 11/21/2007 1888059 12/17/2014 DOIFR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 DOIFR- FR 12195108.1 11/30/2012 2564843 12/26/2018 DOIFR- FR 12195108.1 11/30/2012 2564843 12/26/2018 DOIGB-DIV GB 6784530.5 11/21/2007 1888059 12/17/2014 DOIGB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017							AND MODULATIONS OF ENERGY BIOMARKERS
D01FI-DIV FI 12162555.2 3/30/2012 2471530 1/11/2017 D01FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/25/2018 D01FR FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	ED0001FI	Έ	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DO1FI-DIV FI 12162555.2 3/30/2012 2471530 1/11/2017 D01FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 D01FR FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017						S	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
DO1FI-DIV FI 12162555.2 3/30/2012 2471530 1/11/2017 D01FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 D01FR FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017		***************************************					AND MODULATIONS OF ENERGY BIOMARKERS
D01FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 D01FR FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	ED0001FI-DIV	卫	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DO1FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 D01FR FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR-BIV FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017						:	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
DO1FI-DIV3 FI 12195108.1 11/30/2012 2564843 12/26/2018 D01FR FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017							AND MODULATIONS OF ENERGY BIOMARKERS
DO1FR FR 6784530.5 11/21/2007 1888059 12/17/2014 DO1FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 DO1FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 DO1GB GB 6784530.5 11/21/2007 1888059 12/17/2014 DO1GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	ED0001FI-DIV3	⊐	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DO1FR FR 6784530.5 11/21/2007 1888059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	- Caranto						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
DO1FR FR 6784530.5 11/21/2007 188059 12/17/2014 D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017							AND MODULATIONS OF ENERGY BIOMARKERS
DO1FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	ED0001FR	FR	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
D01FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	38						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
DO1FR-DIV FR 12162555.2 3/30/2012 2471530 1/11/2017 D01FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017					in a state of the		AND MODULATIONS OF ENERGY BIOMARKERS
DO1FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	ED0001FR-DIV	F	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DO1FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017						iloojaa	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
DO1FR- FR 12195108.1 11/30/2012 2564843 12/26/2018 D01GB GB 6784530.5 11/21/2007 1888059 12/17/2014 D01GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017							AND MODULATIONS OF ENERGY BIOMARKERS
001GB GB 6784530.5 11/21/2007 1888059 12/17/2014 001GB-DIV GB 12162555.2 3/30/2012 2471530 1/11/2017	ED0001FR-	7	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
GB 6784530.5 11/21/2007 1888059 12/17/2014 GB 12162555.2 3/30/2012 2471530 1/11/2017	DIV3						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
GB 6784530.5 11/21/2007 1888059 12/17/2014 GB 12162555.2 3/30/2012 2471530 1/11/2017							AND MODULATIONS OF ENERGY BIOMARKERS
GB 12162555.2 3/30/2012 2471530 1/11/2017	ED0001GB	GB	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
GB 12162555.2 3/30/2012 2471530 1/11/2017			55. 15.				MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
GB 12162555.2 3/30/2012 2471530 1/11/2017						***************************************	AND MODULATIONS OF ENERGY BIOMARKERS
MITOCHONDRIAL DISEASES AND MODULATIONS OF ENE	ED0001GB-DIV	GB	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
AND MODULATIONS OF ENE	35	e Lucile	## *			-33 -33 -34	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						***************************************	AND MODULATIONS OF ENERGY BIOMARKERS

£3	Ţ	* Commence of the Commence of	Property of the Party of the Pa	Service of the servic	والمعاولة والمتحددة والمتحدث والمتحدث والمتحددة	
Client Ref	Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001GB-	GB	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3	dan e	1 a	: 4. 0			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
EDOOO1GR	ē	6787530 F	11/21/2007	1000000	10/17/0011	AND MODULATIONS OF ENERGY BIOMARKERS
EDOUGLGK	ş	6/84530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001GR-DIV	GR	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001GR-	GR	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3					in acc	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001HK-DIV	¥	12113337.1	3/11/2008	1173364	11/3/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001HU	Н	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
	-					MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
		o construction of the cons				AND MODULATIONS OF ENERGY BIOMARKERS
ED0001HU-DIV	E	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
	المراجع				******	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IE	m	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
					*******	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
***************************************	-					AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IE-DIV	m	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
3. S.			*******			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IE-DIV3	m	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001IS	S	6784530.5	11/21/2007	1888059	12/17/2014	REDOX: ACTIVE THERAPEUTICS FOR TREATMENT OF
20000	in in					MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IT	=	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
1	+					AND MODULATIONS OF ENERGY BIOMARKERS
FD000TIT-DIV	=	12162555,2	3/30/2012	502017000034214	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IT-DIV3	=	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
					***************************************	AND MODULATIONS OF ENERGY BIOMARKERS
ED0001JP-	5	2013-030630		5631428	10/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV2					ereni iri	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001LT	5	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
					outries.	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
		and the second s				AND MODULATIONS OF ENERGY BIOMARKERS
ED0001LU	5	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001LU-DIV	Ξ	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
					nanahani mpanjari	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
					-	AND MODULATIONS OF ENERGY BIOMARKERS
ED0001LV	7	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
	,				en e	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
					***************************************	AND MODULATIONS OF ENERGY BIOMARKERS
ED0001MC	MC	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
33	::: *******					MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
		***************************************				AND MODULATIONS OF ENERGY BIOMARKERS

Client Ref	Country	Application	Filing Date	Patent	issue Date	Title
ED0001MX	ΜX	MXA2007015006	11/28/2007	304532	10/23/2012	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
			300.000			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
	23 63					AND MODULATIONS OF ENERGY BIOMARKERS
ED0001MX	M X	MXA2010011492	10/19/2010	305574	11/27/2012	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001MX-	×	MXA2012009599	8/17/2012	359292	9/24/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV2	-00	•				MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001NL	Z	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001NL-DIV	Z	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
EDOOOINL-	2	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
				inalianjanjanjanjanjanjanjanjanjanjanjanjanja		AND MODULATIONS OF ENERGY BIOMARKERS
ED0001PL	PL	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001PL-DIV	PL	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001PL-	PL	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
					**************************************	AND MODULATIONS OF ENERGY BIOMARKERS
ED0001PT	PT	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
					מברברכב	MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
2000		- correction				AND MODULATIONS OF ENERGY BIOMARKERS

Client Ref	Country	Application	Filing Date	Patent	Issue Date	Title
יייי דיייייייייייייייייייייייייייייייי	7	ACT COLLEGE	2 /22 /22	Number		
FD000TP1-DIV		12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001RO	RO	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
			مندسد			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
					*******************************	AND MODULATIONS OF ENERGY BIOMARKERS
ED0001RO-DIV	RO	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
	and the					MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
				؞ معارف مارسان مارسان المرابع معارف المرابع معارف المرابع معارف المرابع معارف المرابع معارف المرابع المرابع الم		AND MODULATIONS OF ENERGY BIOMARKERS
ED0001RU	R∪	200702622	12/25/2007	16226	3/30/2012	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
***************************************						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SE	SE	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPE UTICS FOR TREATMENT OF
						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
		***************************************				AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SE-DIV	SE	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
دودورو	نيوندونو <u>.</u>					MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SE-	SE	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
DIV3						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
					***************************************	AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SI	S	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
	******		ירכבריבר			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SI-DIV	S	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
******						MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
	-			بإدران والمستون والمس	***************************************	AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SK	Ş	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF
		33	55			MITOCHONDRIAL DISEASES AND OTHER CONDITIONS
						AND MODULATIONS OF ENERGY BIOMARKERS

***************************************	£.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			-	بنبيبيبيبين فينين فيدود ودود ودود	***************************************
Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001SK-DIV	XX	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001TR	ੜ	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODIJI ATIONS OF ENERGY RIOMARKERS
ED0001TR-DIV	T _R	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF FNERGY BIOMARKERS
ED0001TR- DIV3	TR	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001US	US	11/445,582	6/1/2006	9447006	9/20/2016	REDOX -ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0001US-DIV	US	12/777,179	5/10/2010			REDOX -ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002CA	CA	2622523	3/13/2008	2622523	2/18/2014	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002EA	ĒΑ	200800819	9/15/2006	21818	9/30/2015	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002EP	EP	6814749.5	2/1/2008			TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002HK	Ŧ	8107428.9	7/7/2008		98.	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER

A000000	-		1	direction of the second se	derenderenderenderenderenderenderendere	
Client Ref	Code	Number	Filing Date	Number	Issue Date	Title
						CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002JP-DIV	Q D	2013-098528	5/8/2013	5999816	9/9/2016	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002MX	MX	MXA2008003510	3/12/2008	265350	3/23/2009	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002RU	RU	200800819		21818	9/30/2015	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002US	SN	11/521,887	9/15/2006	7432305	10/7/2008	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0004AU	ΑU	2003287250		2003287250	1/28/2010	IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES
ED0004JP	JP	2005-502210		4599292	10/1/2010	IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES
ED0004US	US	10/696,752	10/29/2003	7491312	2/17/2009	IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES
ED0005CA	Ç	2635280	6/25/2008	2635280	12/12/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005CH-DIV	유	10015055.6	11/26/2010	2332534	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0005CH- DIV3	유	13163805.8	4/15/2013	2617418	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION
ED0005DE	DE	7751472.7	6/23/2008	602007030011.8	4/24/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
*				ŝ		THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISFASES AND OTHER CONDITIONS AND MODITIONS
						OF ENERGY BIOMARKERS
ED0005DE-DIV	PE	10015055.6	11/26/2010	602007056853.6	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
			******			THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL
						DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005DE-	DE	13163805.8	4/15/2013	602007053175.6	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
7.40						THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL
						OF ENERGY BIOMARKERS
ED0005EA	ΕA	200801623		19675	5/30/2014	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS
::						FOR TREATMENT OF MITOCHONDRIAL DISEASES AND
						BIOMARKERS
ED0005EP	EΡ	7751472.7	6/23/2008	1986636	4/24/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS
						FOR TREATMENT OF MITOCHONDRIAL DISEASES AND
				81		BIOMARKERS
ED0005EP-DIV	ΕP	10015055.6	11/26/2010	2332534	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS
						FOR TREATMENT OF MITOCHONDRIAL DISEASES AND
	<u> </u>				inityu	OTHER CONDITIONS AND MODULATION OF ENERGY
EDODOEED	T 0	13163005 0	7 /1 /20/2			BIOMARKERS
DIV3	5	7070000	CT07/CT/#	201/418	11/22/2017	SIDE-CHAIN VARIANTS OF REDUX-ACTIVE THERAPEUTICS
						OTHER CONDITIONS AND MODILI ATION OF ENERGY
						BIOMARKERS
				***************************************	***************************************	

Client Ref	Country	Application	Filing Date	Patent	Issue Date	Title
ED0005FR-DIV	FR	10015055.6	11/26/2010	2332534	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
						DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005FR-	73	13163805.8	4/15/2013	2617418	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
DIV3	· · · · · · · · · · · · · · · · · · ·					THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL
						OF ENERGY BIOMARKERS
ED0005GB	GB	7751472.7	6/23/2008	1986636	4/24/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
, jednosie				world: U		THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL
				- 23		DISEASES AND OTHER CONDITIONS AND MODULATION
ED0005GB-DIV	GB	10015055.6	11/26/2010	2332534	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
						THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL
	n na phirospia		5	0.1.000.100		DISEASES AND OTHER CONDITIONS AND MODULATION
ED0005GB-	GB	13163805.8	4/15/2013	2617418	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
DIV3				00000.00		THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL
						DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005HK	풎	9103886.2	4/27/2009	1124552	1/30/2014	SIDE CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTIC
err vers P						FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODELLATION OF ENERGY
		***************************************				BIOMARKERS
ED0005IT	=	7751472.7	6/23/2008	1986636	4/24/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
					******	THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL
			•		*****	DISEASES AND OTHER CONDITIONS AND MODULATION
	;			· · · · · · · · · · · · · · · · · · ·		OF ENERGY BIOMARKERS
ED0005JP	9	2008-556437	27	5374162	9/27/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE
1000 F 10 T		8				THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL
		á				DISEASES AND OTHER CONDITIONS AND MODULATION
· · · · · · · · · · · · · · · · · · ·		- Companies - Comp	-			OT ENEXGY DICKIARRERU

4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	AT	ED0016AT
7,8-BICYCLOAKYL-CHROMAN DERIVATIVES	1/25/2011	7875607	11/24/2008	12/277,083	SU	ED0015US-DIV
7,8-BICYCLOALKYL-CHROMAN DERIVATIVES	12/30/2008	7470798	9/15/2004	10/941,121	US	ED0015US
TREATMENT OF MITOCHONDRIAL DISEASES	7/28/2015	2580584	3/16/2007	2580584	Ç	ED0014CA
CHROMAN DERIVATIVES	7/29/2014	8791155	9/26/2011	13/245,741	S	ED0013US- DIV2
CHROMAN DERIVATIVES	4/7/2009	7514461	9/15/2004	10/941,125	SU	ED0013US
METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA USING NON-ALPHA TOCOPHEROLS	4/25/2006	7034054	12/14/2001	10/020,450	US	ED0009US
OF ENERGY BIOMARKERS						
THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION						Ç
SIDE-CHAIN VARIANTS OF REDOX-ACTIVE	4/3/2018	9932286	12/29/2015	14/983,330	S	ED0005US-
OF ENERGY BIOMARKERS						
DISEASES AND OTHER CONDITIONS AND MODULATION						
SIDE-CHAIN VARIANTS OF REDOX-ACTIVE	3/8/2016	9278085	2/22/2007	11/710,042	S	ED0005US
OF ENERGY BIOMARKERS						
DISEASES AND OTHER CONDITIONS AND MODULATION	33.000	and desired	· · · · · · · · · · · · · · · · · · ·			
THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL		:				
SIDE-CHAIN VARIANTS OF REDOX-ACTIVE	5/30/2014	19675		200801623	æ	ED0005RU
OF ENERGY BIOMARKERS				***************************************		
DISEASES AND OTHER CONDITIONS AND MODULATION			•••••			
THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL						DIV
SIDE-CHAIN VARIANTS OF REDOX-ACTIVE	5/13/2015	330023	1/2/2012	MXA2012000147	×	ED0005MX-
OF ENERGY BIOMARKERS						
DISEASES AND OTHER CONDITIONS AND MODULATION	in the			·		***
THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL				~~~~	*****	
SIDE-CHAIN VARIANTS OF REDOX-ACTIVE	6/21/2013	310729	6/12/2008	MXA2008007631	 X	ED0005MX
Title	Issue Date	Number	Filing Date	Number	Code	
	•	Patent	7	Application	Country	Clion+ Dof

5/25/2010 2220030	
5/25/2010 2220030	
5/25/2010 2220030	
10/5/2018	1 :
10/16/2015 3018122	1 :
5/25/2010 2220030	:
10/6/2017	
6/4/2010 28911	
5/25/2010 2220030	
10/16/2015 602008057411.3	
5/25/2010 602008042077.9	3.
5/25/2010 2220030	· •
10/16/2015 3018122	
5/25/2010 2220030	1
5/25/2010 2704473	
5/25/2010 2220030	
Number	

	1/13/2016	2220030	5/25/2010	8847883.9	Z	ED0016NL
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES			4/20/2016	MXA2016005111	×	ED0016MX- DIV2
.6 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	4/22/2016	338572	10/21/2013	MXA2013012276	X X	ED0016MX- DIV
	10/21/2013	314400	4/27/2010	MXA2010004622	X X	ED0016MX
	1/13/2016	2220030	5/25/2010	8847883.9	Г	ED0016LU
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES			5/15/2019	2019-091932	JP	ED0016JP- DIV4
	6/5/2015	5755881	4/28/2010	2010-532329	JP	ED0016JP
	1/13/2016	2220030	5/25/2010	8847883.9	Π	ED0016IT
	1/13/2016	2220030	5/25/2010	8847883.9	Æ	ED0016IE
	1/13/2016	2220030	5/25/2010	8847883.9	Н	ED0016HU
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES			9/18/2019	19129816.5	Ę	ED0016HK- DIV2
16 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	6/17/2016	1143804	11/1/2010	10110222.7	Ŧ	ED0016HK
	1/13/2016	2220030	5/25/2010	8847883.9	GR	ED0016GR
	10/10/2018	3018122	10/16/2015	15190273.1	GB	ED0016GB-DIV
16 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	GB	ED0016GB
018 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	10/10/2018	3018122	10/16/2015	15190273.1	FR	ED0016FR-DIV
ate Title	Issue Date	Patent Number	Filing Date	Application Number	Country Code	Client Ref

(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	3/28/2017	2708961	6/10/2010	2708961	CA	ED0018CA
4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/17/2017	9546132	8/18/2015	14/829,534	Sn	ED0016US- DIV2
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	8/27/2013	8519001	5/18/2011	13/110,830	SS	ED0016US-DIV
4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES			12/20/2018	16/228,657	S	ED0016US- CON3
4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/1/2019	10167251	12/9/2016	15/374,916	S	ED0016US- CON2
4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	10/27/2015	9169196	6/21/2013	13/924,363	SN	ED0016US- CON
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	6/28/2011	7968746	11/4/2008	12/264,838	S	ED0016US
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2016/04748	5/25/2010	8847883.9	TR	ED0016TR
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	SK	ED0016SK
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	SI	ED0016SI
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	SE	ED0016SE
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/31/2018	28911	6/4/2010	201000756	RU	ED0016RU
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	RO	ED0016RO
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	PT	ED0016PT
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	РГ	ED0016PL
4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	1/13/2016	2220030	5/25/2010	8847883.9	NO	ED0016NO
Title	Issue Date	Patent Number	Filing Date	Application Number	Country Code	Client Ref

	4/3/2018	2717741	9/3/2010	2717741	S	ED0020CA
	7/28/2015	9090576	3/24/2014	14/223,842	SO	ED0019US-DIV
14 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES	5/6/2014	8716527	10/18/2010	12/919,007	SO	ED0019US
015 2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES	3/13/2015	5710277	9/3/2010	2010-549855	JP	ED0019JP
018 2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES	10/3/2018	2262508	9/21/2010	9717547.5	GB	ED0019GB
018 2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES	10/3/2018	2262508	9/21/2010	9717547.5	FR	ED0019FR
018 2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES	10/3/2018	2262508	9/21/2010	9717547.5	ΕP	ED0019EP
018 2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES	0 10/3/2018	602009054853.0	9/21/2010	9717547.5	DE	ED0019DE
2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES			9/3/2010	2717734	CA	ED0019CA
016 (HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	11/8/2016	9486435	12/30/2014	14/586,516	SO	ED0018US-DIV
1915 (HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	2/10/2015	8952071	10/8/2010	12/811,694	Sn	ED0018US
916 (HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	6/30/2016	23618		201001119	RU	ED0018RU
2014 (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	11/21/2014	5649454	7/7/2010	2010-542313	JP	ED0018JP
(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES			3/17/2011	11102697.9	¥	ED0018HK
(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES			7/26/2010	9700856.9	9	ED0018EP
2016 (HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES	6/30/2016	23618		201001119	EA	ED0018EA
Date	Issue Date	Patent Number	Filing Date	Application Number	Country Code	Client Ref

Client Ref	Country	Application Number	Filing Date	Patent	Issue Date	Title
ED0020JP-DIV	٥	2014-016459	1/31/2014	6131200	4/21/2017	TREATMENT OF HEARING AND BALANCE IMPAIRMENTS
ED0023CA	CA	2729227	12/23/2010	2729227	5/22/2018	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS
ED0023DE	DE	97708820	1/12/2011	602009030208.6	3/25/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023EP	EΡ	97708820	1/12/2011	2303824	3/25/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023GB	GB	97708820	1/12/2011	2303824	3/25/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023IT	口	9770882	1/12/2011	2303824	3/25/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023JP	Ър	2011-516536	12/24/2010	5798481	8/28/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023US	SO	12/997,869	2/15/2011	8716486	5/6/2014	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023US-DIV	S	14/223,932	3/24/2014	9073873	7/7/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0026BR	BR	PI0918139-3	3/10/2011			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026CA	Ş	2736250	3/4/2011	2736250	12/20/2016	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026EP	EP	9792325.4	4/6/2011			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS

Client Ref	Code	Number	Filing Date	Number	Issue Date	Title
ED0026HK	Τ̈́́́	11114109.6	1/20/2012			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026JP- DIV2	JР	2015-055908	3/19/2015	6259410	12/15/2017	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026JP- DIV4	JP	2017-076681	4/7/2017			TREATMENT OF PERVASIVE DEVELOPMENTAL
ED0026JP-	₽	2018-116995	6/20/2018			TREATMENT OF PERVASIVE DEVELOPMENTAL
ED0026MX	××	MXA2011002318	3/1/2011	319696	4/25/2014	TREATMENT OF BERVASIVE DEVELOPMENTAL TREATMENT OF BERVASIVE DEVELOPMENTAL
EDUUZBIXIX	MX	MIXAZULLUUZ318	3/1/2011	3.19696	4/25/2014	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026MX- DIV	<u>₹</u>	MXA2014004966	4/24/2014	363223	3/15/2019	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US	S	12/555,700	9/8/2009	8314153	11/20/2012	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US- CON	US	14/605,937	1/26/2015	9399612	7/26/2016	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US- CON2	Sn	15/208,549	7/12/2016	10105325	10/23/2018	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US- CON3	SN	16/165,985	10/19/2018			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US-DIV	S	13/651,330	10/12/2012	8653144	2/18/2014	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US- DIV2	Sn	14/155,288	1/14/2014	8969420	3/3/2015	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0028CH	Ð.	9821111.3	5/4/2011	2362726	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028DE	뭐	9821111.3	5/4/2011	602009053793.8	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0028EP	EΡ	9821111.3	5/4/2011	2362726	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028FR	FR	9821111.3	5/4/2011	2362726	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028GB	GB	9821111.3	5/4/2011	2362726	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028US	US	13/123,496	5/26/2011	10039722	8/7/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028US- CON	US	16/020,882	6/27/2018			TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0029US- CON3	SN	16/213,927	12/7/2018			TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
ED0030AT	ĄΤ	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030AT-DIV	ΑŢ	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030BE	ВE	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030BE-DIV	ΒE	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030BR	BR	PI0920414-8	4/27/2011	P10920414-8	5/22/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0030CA	CA	2741767	4/27/2011	2741767	9/12/2017	PROCESS FOR THE PRODUCTION OF ALPHA-
ED0030CA-DIV	Ç	2974482	7/25/2017			PROCESS FOR THE PRODUCTION OF ALPHA-
الماريد الماري	***************************************					TOCOTRIENOL AND DERIVATIVES
ED0030CH	웃	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-
			***************************************			TOCOTRIENOL AND DERIVATIVES
ED0030CH-DIV	오	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
		the state of the same of the s	***************************************			TOCOTRIENOL AND DERIVATIVES
ED0030CN	2	200980152635.0	6/27/2011	102264730	4/13/2016	PROCESS FOR THE PRODUCTION OF ALPHA-
						TOCOTRIENOL AND DERIVATIVES
ED0030CN-DIV	2	201610142967.2	3/14/2016	105753829	2/1/2019	PROCESS FOR THE PRODUCTION OF ALPHA-
				***************************************	***************************************	TOCOTRIENOL AND DERIVATIVES
ED0030CZ-DIV	22	15175938.8	7/8/2018	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
	***************************************					I OCO I RIENOL AND DERIVATIVES
ED0030DE	R	9824070.8	5/23/2011	602009033072.1	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-
			***************************************			TOCOTRIENOL AND DERIVATIVES
ED0030DE-DIV	DE	15175938.8	7/8/2015	602009055191,4	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
						TOCOTRIENOL AND DERIVATIVES
ED0030DK	무	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-
				***************************************		TOCOTRIENOL AND DERIVATIVES
ED0030DK-DIV	무	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
	***************************************					TOCOTRIENOL AND DERIVATIVES
ED0030EA	ΕA	201100699	5/27/2011	26417	4/28/2017	PROCESS FOR THE PRODUCTION OF ALPHA-
						TOCOTRIENOL AND DERIVATIVES
ED0030EA-DIV	ΕA	201692046	11/10/2016			PROCESS FOR THE PRODUCTION OF ALPHA-
						TOCOTRIENOL AND DERIVATIVES
ED0030EP	EΡ	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-
	***************************************					TOCOTRIENOL AND DERIVATIVES
ED0030EP-DIV	EΡ	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
						TOCOTRIENOL AND DERIVATIVES
ED0030EP-	Ð	18200523.1	10/15/2018		***************************************	PROCESS FOR THE PRODUCTION OF ALPHA-
DIVZ	3		***************************************	distribution of the second	****	OCO RIENOL AND DERIVATIVES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0030ES	ES	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030ES-DIV	ES	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030FI-DIV	⊐	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030FR	FR	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030FR-DIV	T.R	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030GB	GB	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030GB-DIV	GB	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030GR-DIV	GR	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030HK	픚	12101813.9	2/23/2012	1161876	12/18/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030HK-DIV	¥	16107746.4	7/4/2016	1219718	8/30/2019	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030HU-DIV	НО	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030ID	ō	W00201101700	5/11/2011	IDP0040634	3/24/2016	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IE	Æ	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IE-DIV	m	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IN	Z	3303CHENP2011	5/13/2011	298847	7/13/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IN-DIV	Z	201848006829	2/22/2018			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED00301T	ㅋ	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-
ED0030IT-DIV	=	15175938.8	7/8/2015	502018000038621	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
	***************************************					TOCOTRIENOL AND DERIVATIVES
ED0030JP	Þ	2011-534678	6/14/2011	5775459	7/10/2015	PROCESS FOR THE PRODUCTION OF ALPHA-
						TOCOTRIENOL AND DERIVATIVES
ED0030JP-DIV	<u>-</u>	2014-177733	9/2/2014	6001025	9/9/2016	PROCESS FOR ENRICHMENT AND ISOLATION OF ALPHA-
						TOCOTRIENOL FROM NATURAL EXTRACTS
ED0030JP.	₽	2018-108448	6/6/2018			PROCESS FOR ENRICHMENT AND ISOLATION OF ALPHA-
DIV3			***************************************			TOCOTRIENOL FROM NATURAL EXTRACTS
ED0030JP-	Þ	2019-008496	1/22/2019			PROCESS FOR ENRICHMENT AND ISOLATION OF ALPHA-
DIV4		***************************************			***************************************	TOCOTRIENOL FROM NATURAL EXTRACTS
ED0030LU-DIV	Ξ	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA
	7.4	***************************************	107/001		1 120 120 120	TOCOT MILINOL AND DENIVE STATES
						TOCOTRIENOL AND DERIVATIVES
ED0030MY	N Y	PI2011001873	4/27/2011	157119	5/13/2016	PROCESS FOR THE PRODUCTION OF ALPHA-
					***************************************	TOCOTRIENOL AND DERIVATIVES
ED0030MY-	M	PI2014003438	12/12/2014			PROCESS FOR THE PRODUCTION OF ALPHA-
UIV		***************************************			***************************************	TOCOTRIENOL AND DERIVATIVES
ED0030MY-	₹	P12018002729	12/28/2018			PROCESS FOR THE PRODUCTION OF ALPHA-
DIV2						TOCOTRIENOL AND DERIVATIVES
ED0030NL	2	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-
						TOCOTRIENOL AND DERIVATIVES
ED0030NL-DIV	Z	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
	***************************************					TOCOTRIENOL AND DERIVATIVES
ED0030NO-DIV	NO	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
						TOCOTRIENOL AND DERIVATIVES
ED0030PL	<u>P</u>	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-
	2					TOCOTRIENOL AND DERIVATIVES
ED0030PL-DIV		15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
	**************************************		***************************************			

Client Ref	Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0030PT	PΤ	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030PT-DIV	PΤ	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030RO-DIV	RO	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030RU	R∪	201100699	5/27/2011	26417	4/28/2017	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SE	SE	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SE-DIV	SE	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SG	SG	201103008-7		170993	5/6/2014	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SI-DIV	SI	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SK-DIV	SK	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
ED0030TR	TR	9824070.8	5/23/2011	2015/14511	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030TR-DIV	TR	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-
ED0030US	SO	12/606,923	10/27/2009	8106223	1/31/2012	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030US- CON	S	13/358,451	1/25/2012	8575369	11/5/2013	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030US- CON3	SO	15/068,452	3/11/2016	10071978	9/11/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030US-DIV	Sn	16/127,102	9/10/2018			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0031BR	BR	PI10133771	10/28/2011			FORMULATION OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPTHALMIC DISEASES

ED0034GB	ED0034FR	ED0034FI	ED0034ES	ED0034EP	ED0034EA	ED0034DK	ED0034DE	ED0034CZ	ED0034CN	ED0034CH	ED0034CA	ED0034BR	ED0034BE	ED0034AU	ED0034AT	Client Ref
GB	FR	Ξ	ES	ΕP	EΑ	D X	DE	C2	CN	CH	ÇA	BR	BE	ΑU	АТ	Country Code
10747777	10747777	10747777	10747777	10747777	201200355	10747777	10747777	10747777	201080048363.2	10747777	2772294	112012004167-3	10747777	2010286704	10747777	Application Number
3/19/2012	3/19/2012	3/19/2012	3/19/2012	3/19/2012		3/19/2012	3/19/2012	3/19/2012	***************************************	3/19/2012	2/24/2012	2/24/2012	3/19/2012	3/1/2012	3/19/2012	Filing Date
2470168	2470168	2470168	2470168	2470168	28677	2470168	602010048348.7	2470168	102647981	2470168	2772294		2470168	2010286704	AT-E0966731	Patent Number
1/31/2018	1/31/2018	1/31/2018	1/31/2018	1/31/2018	12/29/2017	1/31/2018	1/31/2018	1/31/2018	9/28/2016	1/31/2018	8/21/2018		1/31/2018	10/20/2016	1/31/2018	Issue Date
METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA	Title

Client Ref	· ·	Sometry	Analication	**	7-1-5-		enterior consequence consequence de la
R GR 10747777 3/19/2012 20180400845 1/31/2018 METHODS CEREBRAL CEREBRAL J HU 10747777 3/19/2012 1815867 1/31/2018 METHODS CEREBRAL IE 10747777 3/19/2012 2470168 1/31/2018 METHODS CEREBRAL J II 10747777 3/19/2012 5785546 7/31/2015 METHODS CEREBRAL J JP 2012-526918 2/23/2012 5785546 7/31/2015 METHODS CEREBRAL X MX MXA2012002374 3/19/2012 2470168 1/31/2018 METHODS CEREBRAL X MX MXA2012002374 3/19/2012 2470168 1/31/2018 METHODS CEREBRAL X MX MXA2012002377 3/19/2012 2470168 1/31/2018 METHODS CEREBRAL D NO 10747777 3/19/2012 2470168 1/31/2018 METHODS CEREBRAL D RO 10747777 3/19/2012 2470168 1/31/2018 METHODS CEREBRAL D RO 10	Client Ref	Code	Number	Filing Date	Number	Issue Date	Title
HU 10747777 3/19/2012 1815867 1/31/2018 IE 10747777 3/19/2012 2470168 1/31/2018 1/31/2018 IE 10747777 3/19/2012 502018000012377.0 1/31/2018	ED0034GR	GR	10747777	3/19/2012	20180400845	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
IE 10747777 3/19/2012 2470168 1/31/2018 1/	ED0034HU	₹	10747777	3/19/2012	1815867	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
IT 10747777 3/19/2012 502018000012377.0 1/31/2018 1/31	ED00341E	m	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CFRERRAL ISCHEMIA
JP 2012-526918 2/23/2012 5785546 7/31/2015 I LU 10747777 3/19/2012 2470168 1/31/2018 X MX MXA22012002374 3/19/2012 2470168 1/31/2018 N NL 10747777 3/19/2012 2470168 1/31/2018 PL 10747777 3/19/2012 2470168 1/31/2018 PT 10747777 3/19/2012 2470168 1/31/2018 D RO 10747777 3/19/2012 2470168 1/31/2018 J RU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SS 10747777 3/19/2012 2470168 1/31/2018	ED0034IT	=	10747777	3/19/2012	502018000012377.0	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CFRERRAL ISCHEMIA
LU 10747777 3/19/2012 2470168 1/31/2018 X MMX MXA2012002374 337990 3/30/2016 - NL 10747777 3/19/2012 2470168 1/31/2018 D NO 10747777 3/19/2012 2470168 1/31/2018 PT 10747777 3/19/2012 2470168 1/31/2018 PRO 10747777 3/19/2012 2470168 1/31/2018 PRU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SI 10747777 3/19/2012 2470168 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034JP	JP	2012-526918	2/23/2012	5785546	7/31/2015	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
X MX MXA2012002374 337990 3/30/2016 - NL 10747777 3/19/2012 2470168 1/31/2018 D NO 10747777 3/19/2012 2470168 1/31/2018 PL 10747777 3/19/2012 2470168 1/31/2018 PT 10747777 3/19/2012 2470168 1/31/2018 D RO 10747777 3/19/2012 2470168 1/31/2018 J RU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SI 10747777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034LU	ΓU	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
NL 10747777 3/19/2012 2470168 1/31/2018 D NO 10747777 3/19/2012 2470168 1/31/2018 PL 10747777 3/19/2012 2470168 1/31/2018 PT 10747777 3/19/2012 2470168 1/31/2018 D RO 10747777 3/19/2012 2470168 1/31/2018 J RU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SI 107477777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034MX	MX	MXA2012002374		337990	3/30/2016	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
D NO 10747777 3/19/2012 2470168 1/31/2018 PL 10747777 3/19/2012 2470168 1/31/2018 PT 10747777 3/19/2012 2470168 1/31/2018 D RO 10747777 3/19/2012 2470168 1/31/2018 J RU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SI 10747777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034NL	ΝĽ	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
PL 10747777 3/19/2012 2470168 1/31/2018 PT 10747777 3/19/2012 2470168 1/31/2018 D RO 10747777 3/19/2012 2470168 1/31/2018 J RU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SI 10747777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034NO	NO	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
PT 10747777 3/19/2012 2470168 1/31/2018 D RO 10747777 3/19/2012 2470168 1/31/2018 J RU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SI 10747777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034PL	PL	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
RO 10747777 3/19/2012 2470168 1/31/2018 RU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SI 10747777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034PT	PΤ	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
RU 201200355 28677 12/29/2017 SE 10747777 3/19/2012 2470168 1/31/2018 SI 10747777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034RO	RO	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
SE 10747777 3/19/2012 2470168 1/31/2018 SI 10747777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034RU	R∪	201200355		28677	12/29/2017	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
SI 10747777 3/19/2012 P-201031644 1/31/2018 SK 10747777 3/19/2012 2470168 1/31/2018	ED0034SE	SE	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
SK 10747777 3/19/2012 2470168 1/31/2018	ED0034SI	SI	10747777	3/19/2012	P-201031644	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
	ED0034SK	SK	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0034TR	궁	10747777	3/19/2012	2018/05682	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0040AT	ĄΤ	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
			-			TOCOTRIENOL QUINONES
ED0040BE	BE	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
						NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
		***************************************				COTRIENOL QUINONES
ED0040BR	B _Z	PI10133763	10/28/2011			TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
						TOCOTRIENOL QUINONES
ED0040CA	ξ	2777479	10/27/2011	2777479	10/17/2017	TREATMENT OF LEBER'S HEREDITARY OPTIC
						NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040CH	£	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
						NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
	}	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				TOCOTRIENOL QUINONES
ED0040CZ	22	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
						TOCOTRIENOLOLINONES
ED0040DE	DЕ	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
:						NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
				in a second seco		TOCOTRIENOL QUINONES
ED0040DK	무	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
					Locoso	NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
				and the second s		TOCOTRIENOL QUINONES
ED0040EA	ΕA	201101575	11/25/2011	31126	11/30/2018	TREATMENT OF DOMINANT OPTIC ATROPHY WITH
						TOCOTRIENOL QUINONES
ED0040EP	ΕP	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
	******					NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
				elektroniste karanta k		TOCOTRIENOL QUINONES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0040ES	ES	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
			frances	8	*********	NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
1	1			- The second control of the second control o		TOCOTRIENOL QUINONES
ED0040F1	<u>a</u>	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
						TOCOTRIENOL QUINONES
ED0040FR	R	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
						NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
						TOCOTRIENOL QUINONES
ED0040GB	GB	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
<u> </u>						NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
)	7017				TOCOTRIENOL QUINONES
ED0040GR	ç	10/15650./	11/1//2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
	ALCO LUCE					TOCOTRIENOL OLINONES
ED0040HU	E	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
	سننب					NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
	مانست					TOCOTRIENOL QUINONES
ED0040IE	m	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
2						NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
	i					TOCOTRIENOL QUINONES
ED0040IT	=	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
					٠	NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
						TOCOTRIENOL QUINONES
ED0040LU	Ξ	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC
÷-	55444,54					NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
						TOCOTRIENOL QUINONES
ED0040MX	X ×	MXA2011011309	10/26/2011	336800	2/2/2016	TREATMENT OF LEBER'S HEREDITARY OPTIC
		- 報				NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
						TOCOTRIENOL QUINONES

Client Ref	Country	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0040NL	Z	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
ED0040NO	NO O	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040PL	ЪГ	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040PT	P	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040RO	RO	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040RU	RU	201101575	11/25/2011	31126	11/30/2018	TREATMENT OF DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040SE	SE	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040SI	SI	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040SK	SK	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040TR	TR	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040US- CON	SO	13/859,592	4/9/2013	9370496	6/21/2016	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES

Client Ref	Code	Number	Filing Date	Patent Number	Issue Date	Title
ED0040US- CON2	S	15/178,423	6/9/2016	10195161	2/5/2019	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH
ED0044AU	ΑU	2011285619	2/16/2013	2011285619	3/16/2017	TREATMENT OF MITOCHONDRIAL DISEASES WITH
EDODAAID	ō	2012_F222/2	ɔ/⊑/ɔ∩₁ɔ	CONETON		NAPHTHOQUINONES
ED0044JP	<u>.</u>	2013-523342	2/5/2013	6045494	11/25/2016	TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES
ED0045AU	ΑU	2011245384	11/14/2012	2011245384	8/18/2016	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045JP	JP	2013-508167	10/25/2012	5902673	3/18/2016	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045JP-DIV	JP	2016-046881	3/10/2016	6266674	1/5/2018	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045MX	×	MXA2012012518		337594	3/11/2016	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISFASES
ED0045MX- DIV	 XX	MXA2015010910	8/21/2015		33	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045MY	MΥ	PI2012004738	10/25/2012			FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045ZA	ZA	201208535	11/13/2012	201208535	6/29/2016	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0048US	Sn	14/124,671	4/30/2014	9464016	10/11/2016	CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0051EP	EP	12807735.1	2/5/2014			TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONE
ED0051JP	Jp	2014-519307	1/3/2014			TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONE
ED0051US- CON	SO	16/019,363	6/26/2018			TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0054CA	CA	2842486	1/20/2014			METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054EP	9	12814970.5	2/12/2014			METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054JP-DIV	JÞ	2017-005308	1/16/2017	6568880	8/9/2019	METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054US	SN	14/233,734	5/19/2014	9162957	10/20/2015	METHODS FOR OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054US- CON	SN	14/850,855	9/10/2015	9567279	2/14/2017	METHODS FOR OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054US- CON2	SO	15/411,861	1/20/2017	10029971	7/24/2018	METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054US- CON3	SN	16/040,281	7/19/2018	10202325	2/12/2019	METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0055JP	JP	2015-531249	3/5/2015	6393684	8/31/2018	MODULATION OF REDOX STATUS OF INDIVIDUALS
ED0056CA	CA	2906150	9/11/2015			RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0056US	SS	13/837,872	3/15/2013	9296712	3/29/2016	RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0056US-CIP	SS	14/776,683	9/14/2015	9670170	6/6/2017	RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0058US-CIP	S	14/776,688	9/14/2015	9868711	1/16/2018	PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0059MX	ΧX	MXA2015016014				CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0078IL	F	252953	6/15/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078IN	Z	201717024682	7/12/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1.4-DIENYL)BUTANAMIDE
ED0078JP	JÞ	2017-532088	6/15/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCI OHFXA-1 4-DIFNYI)RI ITANAMIDF
ED0078KR	KR	10-2017-7019399	7/12/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1.4-DIENYL)BUTANAMIDE
ED0078MX	MX	MX/a/2017/008063	6/16/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078NZ	ZN	733528	7/6/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078RU	R∪	2017124714	7/12/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY:2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078US	SO	15/536,603	6/15/2017	10251847	4/9/2019	POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078US- CON2	SO	16/354,070	3/14/2019			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078ZA	ZA	2017/04639	7/10/2017		*	POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENY1)BUTANAMIDE
ED0096AU	ΑU	2016369616	6/18/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-

Client Ref	Country Code	Application Number	Filing Date	Patent	Issue Date	Title
						BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096CA	Ş	3008849	6/15/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-
						BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096CN	CN	201680082001.2	8/16/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY,
(1,000 1)	ررزرررز	مندستند				HETEROARYLOXY, ALKOXY, AND AMINE 1,4-
		***************************************				BENZOQUINONE DERIVATIVES FOR TREATMENT OF
				والتاكيد والمالية وا		OXIDATIVE STRESS DISORDERS
ED0096EP	EP	16822869	7/4/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY,
						HETEROARYLOXY, ALKOXY, AND AMINE 1,4-
66			entra and		*****	BENZOQUINONE DERIVATIVES FOR TREATMENT OF
FDOOGHK	ΗK	10133775	חוחכ/ ככל וי			OXIDATIVE STRESS DISORDERS
330033		2.20				HETEROARYLOXY ALKOXY AND AMINE 1 A
						BENZOQUINONE DERIVATIVES FOR TREATMENT OF
***************************************	district the second sec				***************************************	OXIDATIVE STRESS DISORDERS
ED0096IN	Z	201817026571	7/17/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY,
						HETEROARYLOXY, ALKOXY, AND AMINE 1,4-
		- 25				DAID VELOCIONONE DESIDATIVES FOR TREATMENT OF
ED0096JP	JP	2018-531554	6/15/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY,
					ggilait.	HETEROARYLOXY, ALKOXY, AND AMINE 1,4-
	133					BENZOQUINONE DERIVATIVES FOR TREATMENT OF
		***************************************				OXIDATIVE STRESS DISORDERS
ED0096MX	X ×	MX/a/2018/007389	6/15/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY,
			·······			HETEROARYLOXY, ALKOXY, AND AMINE 1,4-
	15 155	27				BENZOQUINONE DERIVATIVES FOR TREATMENT OF
7	5					OXIDATIVE STRESS DISORDERS
ED0096US	S	16/063,201	6/15/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY,
						HETEROARYLOXY, ALKOXY, AND AMINE 1,4-

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
						BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0097EP	ЕP	15820772	7/7/2017			METHODS FOR CHIRAL RESOLUTION OF TROLOX
ED0099EP	Ę	16826530.4	7/4/2018			IMPROVED METHODS FOR ENRICHING ALPHA-
		and the second s				TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
ED0099IN	Z	201817026439	7/16/2018		83.11	IMPROVED METHODS FOR ENRICHING ALPHA-
						TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
ED0099JP	JP	2018-531506	6/15/2018			IMPROVED METHODS FOR ENRICHING ALPHA-
	-					TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
ED0099US	SU	16/063,035	6/15/2018	-		IMPROVED METHODS FOR ENRICHING ALPHA-
		٠				TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
ED0103CA	CA	3011293	7/11/2018		actual	TOCOPHEROL AND TOCOTRIENOL QUINONE
						DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR
		والمتعادة إيداء والمتاريد والمتاريد والمتاريد والمتاريد والمتاريد والمتاريد والمتاريد والمتاريد والمتاريد				DECREASING HYDROGEN SULFIDE LEVELS
ED0103JP	Þ	2018-555447	7/11/2018			TOCOPHEROL AND TOCOTRIENOL QUINONE
						DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR
	***************************************			Tipperson of the section of the sect		DECREASING HYDROGEN SULFIDE LEVELS
ED0116US	S	16/345,677	4/26/2019			METHODS FOR ANALYZING P-HYDROQUINONE LEVELS
	***************************************			rengiere give existed dispensable discussioning contribu		AND RATIOS
ED0117CN	2	201780070427.0	5/14/2019			2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-
	•••••					ONE COMPOUNDS OR PHARMACEUTICALLY
E						ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO
						RELATED APPLICATIONS
ED0117EP	ΕP	17817338.1	5/24/2019			2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-
	*******		٠		anaingin	ONE COMPOUNDS OR PHARMACEUTICALLY
	÷***					ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO
				***************************************		RELATED APPLICATIONS
ED0117JP-PC	JP	2019-524868	5/13/2019			2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-
			************		******	ONE COMPOUNDS OR PHARMACEUTICALLY
Louise					******	ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO
						RELATED APPLICATIONS

	ŕ	٠	÷
		^	•
- (ī	١

RECORDED: 07/14/2020

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	e Title
ED0117US	Sn	16/349,940	5/14/2019			2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-
	200 A			žž		ONE COMPOUNDS OR PHARMACEUTICALLY
	66					ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO
						RELATED APPLICATIONS
ED0121PCT	W0	PCT/US2018/027682 4/14/2018	4/14/2018		:	METHODS AND COMPOSITIONS FOR TREATMENT OF
		The state of the s				INFLAMMATION AND OXIDATIVE STRESS
ED0121US	S	16/605,192	10/14/19			METHODS AND COMPOSITIONS FOR TREATMENT OF
						INFLAMMATION AND OXIDATIVE STRESS
ED0123US	S	15/675,364	8/11/2017		30.1	Distributed Systems and Methods for Learning About a
			***************************************			Bioprocess from Redox Indicators and Local Conditions
ED0123US-CIP	SN	15/702,885	9/13/2017			Redox-related context adjustments to a reference
						bioprocess model used in learning system and methods
						based on redox indicators
ED0123US-	S	15/785,415	10/16/2017			Redox-related context adjustments to a bioprocess
CIP2	0001.000		************	عندنده	d milio	monitored by learning systems and methods based on
						redox indicators